Department of Pharmaceutical Engineering & Technology (formerly Department of Pharmaceutics), Indian Institute of Technology (Banaras Hindu University), Varanasi 221005, Uttar Pradesh, India; Department of Pharmacy, Moti Lal Nehru Medical College, Allahabad 211002, Uttar Pradesh, India.
Department of Pharmaceutical Engineering & Technology (formerly Department of Pharmaceutics), Indian Institute of Technology (Banaras Hindu University), Varanasi 221005, Uttar Pradesh, India.
Int J Biol Macromol. 2018 Sep;116:394-408. doi: 10.1016/j.ijbiomac.2018.04.179. Epub 2018 May 7.
Considering alarming projections in the prevalence of periodontitis, following study was undertaken to develop chitosan-vanillin crosslinked microspheres loaded in-situ gel (MLIG) implants containing ornidazole and doxycycline hyclate for the treatment of pocket infections. Firstly, microspheres were formulated and optimized using response surface methodology for particle size <50 μm, entrapment efficiency >80%, in-vitro drug release (T) >7 days and acceptable mucoadhesion. Further, MLIG were optimized for gelation temperature of 34-37 °C and viscosity <1000 cps respectively. FTIR, DSC and XRD graphs disclosed compatibility and alterations in crystallinity of drugs. In-vitro dissolution study demonstrated non-Fickian type of drug release mechanism for twelve days. Stability studies ascertained MLIG implants were sterilizable and stable for about 11.29 months on refrigeration. The formulations exhibited significant (p < 0.001) antimicrobial activity against Staphylococcus aureus, Escherichia coli, and Enterococcus faecalis, and were found biocompatible and biodegradable during preclinical studies. Ligature-induced periodontal rat model, corroborated significant growth (p < 0.05) of gingival tissue after two weeks. Clinical trials revealed, intra-pocket administration of MLIG along with SRP provided significant reduction in clinical parameters as compared to SRP alone. Conclusively, antimicrobials incorporated thermosensitive, biodegradable, mucoadhesive and syringeable MLIG implants appeared as better option for the treatment of periodontitis.
考虑到牙周炎患病率的惊人预测,本研究旨在开发壳聚糖-香草醛交联载有奥硝唑和盐酸多西环素的原位凝胶(MLIG)植入物,用于治疗袋内感染。首先,采用响应面法对微球进行配方优化,使其粒径<50μm、包封效率>80%、体外药物释放(T)>7天且具有可接受的粘膜粘附性。此外,还对 MLIG 进行了优化,使其凝胶化温度为 34-37°C,粘度<1000cps。FTIR、DSC 和 XRD 图谱显示药物的相容性和结晶度发生了变化。体外溶解研究表明,药物释放机制为十二天的非菲克扩散型。稳定性研究确定 MLIG 植入物可通过灭菌,冷藏条件下约 11.29 个月稳定。这些制剂对金黄色葡萄球菌、大肠杆菌和粪肠球菌表现出显著的(p<0.001)抗菌活性,且在临床前研究中被发现具有生物相容性和可生物降解性。结扎诱导的牙周大鼠模型表明,两周后牙龈组织明显生长(p<0.05)。临床试验表明,与单独使用 SRP 相比,将 MLIG 注入袋内与 SRP 联合使用可显著降低临床参数。综上所述,含有抗生素的温敏、可生物降解、粘膜粘附和可注射性的 MLIG 植入物似乎是治疗牙周炎的更好选择。